# Public cell-therapy foundries at cancer centres for academics and start-ups

Source: https://onco.cc/ideas/idea-reg-public-cell-therapy-foundries/  
OnCo record `idea-reg-public-cell-therapy-foundries` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Building a cell-therapy factory costs tens of millions, so most good academic ideas never reach patients. Shared public facilities would give them a route to the clinic.

## Summary

The UK Cell and Gene Therapy Catapult, Canada's CCRM and several US academic GMP facilities show that shared, publicly funded manufacturing can carry academic products through early trials. The proposal is a national network of foundries co-located with cancer centres, each with standardised closed automated platforms, a shared quality system, and transparent booking and pricing, funded to provide first-in-human manufacturing at marginal cost for academic and start-up programmes, with a fast route for successful products into the hospital-made network or industry.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Foundry networks double the number of academic cell-therapy INDs per year in participating countries within five years and cut the cost of a first-in-human manufacturing campaign by at least half.
- Rationale: Manufacturing access, not scientific quality, is the stated limiting factor for most academic cell-therapy programmes; shared infrastructure has the same economics as sequencing cores and cryo-EM facilities.
- Proposed test: Fund three foundries, track INDs supported, cost per campaign and time from award to first patient, and compare with academic programmes in regions without foundry access.
- Maturity: early-clinical
- Actor: policy

## Sources

- Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018): https://doi.org/10.1001/jamaoncol.2018.0977

## Connected records

- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [TCR-T cell therapy](https://onco.cc/technologies/tcr-t/), [TIL therapy](https://onco.cc/technologies/til-therapy/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/), [The valley of death between lab and product](https://onco.cc/bottlenecks/b-translational-valley/)
- key papers: [Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy](https://onco.cc/key-papers/paper-hernandez-jama-oncol/)

---
JSON: https://onco.cc/api/v1/entities/idea-reg-public-cell-therapy-foundries.json